Intrathecal substance P-saporin for the treatment of intractable cancer pain

Hugh Nymeyer, Douglas A. Lappi, Denise Higgins, Carl E. Noe, Arthur E. Frankel

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.

Original languageEnglish (US)
Title of host publicationTechniques of Neurolysis
PublisherSpringer International Publishing
Pages197-206
Number of pages10
ISBN (Electronic)9783319276076
ISBN (Print)9783319276052
DOIs
StatePublished - Jan 1 2016

Fingerprint

Intractable Pain
Immunotoxins
Substance P
Biological Toxins
Therapeutics
Pain
Clinical Trials, Phase I
History
substance P-saporin
Cancer Pain
Safety
Neurons

Keywords

  • Allodynia pain
  • Hyperalgesia
  • NK1
  • SP-SAP
  • Substance p

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Nymeyer, H., Lappi, D. A., Higgins, D., Noe, C. E., & Frankel, A. E. (2016). Intrathecal substance P-saporin for the treatment of intractable cancer pain. In Techniques of Neurolysis (pp. 197-206). Springer International Publishing. https://doi.org/10.1007/978-3-319-27607-6_13

Intrathecal substance P-saporin for the treatment of intractable cancer pain. / Nymeyer, Hugh; Lappi, Douglas A.; Higgins, Denise; Noe, Carl E.; Frankel, Arthur E.

Techniques of Neurolysis. Springer International Publishing, 2016. p. 197-206.

Research output: Chapter in Book/Report/Conference proceedingChapter

Nymeyer, H, Lappi, DA, Higgins, D, Noe, CE & Frankel, AE 2016, Intrathecal substance P-saporin for the treatment of intractable cancer pain. in Techniques of Neurolysis. Springer International Publishing, pp. 197-206. https://doi.org/10.1007/978-3-319-27607-6_13
Nymeyer H, Lappi DA, Higgins D, Noe CE, Frankel AE. Intrathecal substance P-saporin for the treatment of intractable cancer pain. In Techniques of Neurolysis. Springer International Publishing. 2016. p. 197-206 https://doi.org/10.1007/978-3-319-27607-6_13
Nymeyer, Hugh ; Lappi, Douglas A. ; Higgins, Denise ; Noe, Carl E. ; Frankel, Arthur E. / Intrathecal substance P-saporin for the treatment of intractable cancer pain. Techniques of Neurolysis. Springer International Publishing, 2016. pp. 197-206
@inbook{de1e359a8a0a45c68fee0f905cc8934f,
title = "Intrathecal substance P-saporin for the treatment of intractable cancer pain",
abstract = "Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.",
keywords = "Allodynia pain, Hyperalgesia, NK1, SP-SAP, Substance p",
author = "Hugh Nymeyer and Lappi, {Douglas A.} and Denise Higgins and Noe, {Carl E.} and Frankel, {Arthur E.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-27607-6_13",
language = "English (US)",
isbn = "9783319276052",
pages = "197--206",
booktitle = "Techniques of Neurolysis",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Intrathecal substance P-saporin for the treatment of intractable cancer pain

AU - Nymeyer, Hugh

AU - Lappi, Douglas A.

AU - Higgins, Denise

AU - Noe, Carl E.

AU - Frankel, Arthur E.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.

AB - Substance P-saporin (SP-SAP) has covalent bonds between the biological toxin, saporin (SAP), and the endogenous peptide, substance P (SP). SAP targets the toxin to the subset of neurons expressing the NK1 receptor. SP-SAP is currently in a phase I clinical trial and is unique as it is the only targeted toxin for pain to undergo human testing. This chapter reviews the history of SP-SAP and related NK1-receptor targeted toxins, animal data on the safety and efficacy of SP-SAP for the treatment of pain (in light of the results of NK1 receptor antagonists and knockouts/knockdowns of either SP or the NK1 receptor), and mechanisms of action of SP-SAP.

KW - Allodynia pain

KW - Hyperalgesia

KW - NK1

KW - SP-SAP

KW - Substance p

UR - http://www.scopus.com/inward/record.url?scp=84978312643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978312643&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27607-6_13

DO - 10.1007/978-3-319-27607-6_13

M3 - Chapter

AN - SCOPUS:84978312643

SN - 9783319276052

SP - 197

EP - 206

BT - Techniques of Neurolysis

PB - Springer International Publishing

ER -